BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Stock Report

Market Cap: US$1.6b

BioCryst Pharmaceuticals Management

Management criteria checks 4/4

BioCryst Pharmaceuticals' CEO is Jon Stonehouse, appointed in Jan 2007, has a tenure of 18.08 years. total yearly compensation is $4.78M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $7.40M. The average tenure of the management team and the board of directors is 5 years and 5.5 years respectively.

Key information

Jon Stonehouse

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage13.9%
CEO tenure18.1yrs
CEO ownership0.5%
Management average tenure5yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 09

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29
Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

Oct 11

BioCryst Pharmaceuticals promotes Sheridan to development chief

Sep 14

BioCryst wins FDA’s Orphan Drug status for bone disorder therapy

Aug 31

BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M

Aug 25

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

CEO Compensation Analysis

How has Jon Stonehouse's remuneration changed compared to BioCryst Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$146m

Mar 31 2024n/an/a

-US$209m

Dec 31 2023US$5mUS$666k

-US$227m

Sep 30 2023n/an/a

-US$236m

Jun 30 2023n/an/a

-US$243m

Mar 31 2023n/an/a

-US$226m

Dec 31 2022US$7mUS$640k

-US$247m

Sep 30 2022n/an/a

-US$193m

Jun 30 2022n/an/a

-US$210m

Mar 31 2022n/an/a

-US$194m

Dec 31 2021US$7mUS$583k

-US$184m

Sep 30 2021n/an/a

-US$227m

Jun 30 2021n/an/a

-US$214m

Mar 31 2021n/an/a

-US$209m

Dec 31 2020US$6mUS$567k

-US$183m

Sep 30 2020n/an/a

-US$125m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$115m

Dec 31 2019US$2mUS$550k

-US$109m

Sep 30 2019n/an/a

-US$134m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$107m

Dec 31 2018US$4mUS$550k

-US$101m

Compensation vs Market: Jon's total compensation ($USD4.78M) is about average for companies of similar size in the US market ($USD5.31M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Stonehouse (63 yo)

18.1yrs

Tenure

US$4,777,778

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director18.1yrsUS$4.78m0.45%
$ 7.4m
Anthony Doyle
Senior VP4.8yrsUS$1.79m0.055%
$ 893.0k
Alane Barnes
Senior VP18.4yrsUS$1.93m0.10%
$ 1.7m
Helen Thackray
Chief Research & Development Officer3.9yrsUS$2.39m0.070%
$ 1.1m
Charles Gayer
Senior VP & Chief Commercial Officer5.1yrsUS$1.74m0.11%
$ 1.9m
John Bluth
Chief Communications Officerno datano datano data
Stephanie Angelini
Chief People Officerno datano datano data
William Sheridan
Chief Development Officer16.6yrsUS$2.66mno data
Yarlagadda Babu
Chief Discovery Officer11.3yrsUS$2.57mno data
Jinky Rosselli
Chief Data & Insights Officer3.3yrsno datano data
Philip George
Chief Strategy Officer2.4yrsno datano data
Clayton Fletcher
Chief Business Development Officer2.1yrsno datano data

5.0yrs

Average Tenure

57yo

Average Age

Experienced Management: BCRX's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Executive Director18.1yrsUS$4.78m0.45%
$ 7.4m
Vincent Milano
Independent Director3.6yrsUS$434.82k0.033%
$ 547.2k
Stephen Aselage
Independent Director6.1yrsUS$446.90k0.024%
$ 387.8k
Alan Levin
Independent Director5yrsUS$434.54k0.014%
$ 222.9k
George Abercrombie
Independent Director13.3yrsUS$432.74k0.0062%
$ 101.6k
Theresa Heggie
Independent Director6.2yrsUS$433.57k0.022%
$ 363.6k
Nancy Hutson
Independent Chair13.1yrsUS$470.30k0.039%
$ 630.5k
Steven K. Galson
Independent Director3.4yrsUS$424.40k0.017%
$ 274.9k
A. Sanders
Independent Director3yrsUS$423.15k0.010%
$ 165.3k
Amy McKee
Independent Director3.4yrsUS$422.32k0.010%
$ 165.9k

5.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: BCRX's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 20:55
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG